Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Evogliptin

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Evogliptin
Clinical data
Trade namesSuganon
Other namesDA-1229
Routes of
administration		By mouth
ATC code
Identifiers
  • (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-{[(2-methyl-2-propanyl)oxy]methyl}-2-piperazinone
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC19H26F3N3O3
Molar mass401.430 g·mol−1
3D model (JSmol)
  • CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](Cc2cc(c(cc2F)F)F)N
  • InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
  • Key:LCDDAGSJHKEABN-MLGOLLRUSA-N

Evogliptin (INN; trade namesSuganon,Evodine) is anantidiabetic drug in thedipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.[1] It was developed by theSouth Korean pharmaceutical companyDong-A ST and is approved for use in South Korea[2] and Russia.[3] In a meta-analysis involving data from 6 randomized controlled trials (887 patients), Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin.[4]

References

[edit]
  1. ^McCormack PL (November 2015). "Evogliptin: First Global Approval".Drugs.75 (17):2045–9.doi:10.1007/s40265-015-0496-5.PMID 26541763.S2CID 46450821.
  2. ^"Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015. Archived fromthe original on June 30, 2022. RetrievedFebruary 1, 2017.
  3. ^"Evodine (evogliptin) film-coated tablets. Full prescribing information".Russian State Register of Medicines (in Russian).
  4. ^Dutta D, Bhattacharya S, Krishnamurthy A, Sharma LK, Sharma M (Nov 2020)."Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis".Indian J Endocrinol Metab.24 (5):434–445.doi:10.4103/ijem.IJEM_418_20.PMC 7810058.PMID 33489850.
Oraldiabetes medication,insulins andinsulin analogues, and other drugs used in diabetes (A10)
Fast-acting
Short-acting
Long-acting
Ultra-long-acting
Inhalable
  • Exubera‡
  • Afrezza
Oral
Non-insulins
Insulin sensitizers
Biguanides
TZDs ("-glitazones") andPPAR agonists
Dual PPAR agonists
Amylin analogues andDACRAs
Secretagogues
K+ATP
Sulfonylureas
Meglitinides ("-glinides")
GLP-1 receptor agonists
GLP1 poly-agonist peptides
DPP-4 inhibitors ("-gliptins")
Other
Aldose reductase inhibitors
Alpha-glucosidase inhibitors
SGLT2 inhibitors ("-gliflozins")
Other
Combinations
Stub icon

Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Evogliptin&oldid=1253368079"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp